|
Advancing the Standards of Care in VWD
CSL Behring provides an educational grant that supports the Advancing the
Standards of Care in VWD CME series for physicians. The series is
cosponsored by ENA Global Medical Communications and the Postgraduate
Institute for Medicine (PIM) and is offered as Web casts with a
teleconference call-in option.
If you would like to register for these Web casts or view
archived Web casts please view the
presentations offered in this series.
Educational Opportunities for Nurses
Supported by an educational grant from CSL Behring, this CE activity is a
review of an NHF symposium about VWD and its treatment. After completion of
this activity, nurses may obtain CE contact hours, and the transcript can be
downloaded right from the website.
New Nurse Workshop
We also sponsor the New Nurse Workshop, a comprehensive nurse-education seminar
on bleeding-disorder management. For more information or to request that your
local representative contact you, please call CSL Behring Medical Affairs at
1-800-504-5434.
Medical Science Liaisons
In addition, we have medical science liaisons who present educational sessions
to physician and nurse practitioner groups. For more information or to request
that your local representative contact you, please call CSL Behring Medical
Affairs at 1-800-504-5434.
Important Safety Information
Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized, Humate-P® is indicated in adult patients for treatment and prevention of bleeding in hemophilia A (classical hemophilia). Humate-P® is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate.
Humate-P® is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations or to any of its components.
Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement, especially in the setting of known risk factors for thrombosis. Caution should be exercised and antithrombotic measures considered.
Humate-P® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
Although few adverse reactions have been reported the most common are allergic-anaphylactic reactions, including urticaria, chest tightness, rash, pruritus, edema, shock, chills and fever, and hypervolemia. For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding.
Please see accompanying full prescribing information for Humate-P®.
The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.
|||
||
© CSL Behring 2008. The product information presented on this site is intended for US residents only.
|
